Second Order Gravitational Self-Force

The second-order gravitational self-force on a small body is an important problem for gravitational-wave astronomy of extreme mass-ratio inspirals. We give a first-principles derivation of a prescription for computing the first and second perturbed metric and motion of a small body moving through a vacuum background spacetime. The procedure involves solving for a "regular field" with a specified (sufficiently smooth) "effective source", and may be applied in any gauge that produces a sufficiently smooth regular field

Gauge and Averaging in Gravitational Self-force

A difficulty with previous treatments of the gravitational self-force is that an explicit formula for the force is available only in a particular gauge (Lorenz gauge), where the force in other gauges must be found through a transformation law once the Lorenz gauge force is known. For a class of gauges satisfying a ``parity condition'' ensuring that the Hamiltonian center of mass of the particle is well-defined, I show that the gravitational self-force is always given by the angle-average of the bare gravitational force. To derive this result I replace the computational strategy of previous work with a new approach, wherein the form of the force is first fixed up to a gauge-invariant piece by simple manipulations, and then that piece is determined by working in a gauge designed specifically to simplify the computation. This offers significant computational savings over the Lorenz gauge, since the Hadamard expansion is avoided entirely and the metric perturbation takes a very simple form. I also show that the rest mass of the particle does not evolve due to first-order self-force effects. Finally, I consider the ``mode sum regularization'' scheme for computing the self-force in black hole background spacetimes, and use the angle-average form of the force to show that the same mode-by-mode subtraction may be performed in all parity-regular gauges. It appears plausible that suitably modified versions of the Regge-Wheeler and radiation gauges (convenient to Schwarzschild and Kerr, respectively) are in this class

A Gluing Construction Regarding Point Particles in General Relativity

We develop a gluing construction which adds scaled and truncated asymptotically Euclidean solutions of the Einstein constraint equations to compact solutions with potentially non-trivial cosmological constants. The result is a one-parameter family of initial data which has ordinary and scaled "point-particle" limits analogous to those of Gralla and Wald ("A rigorous derivation of gravitational self-force," Class. Quantum Grav. 2008). In particular, we produce examples of initial data which generalize Schwarzschild - de Sitter initial data and gluing theorems of IMP-type

Stellar Populations of Highly Magnified Lensed Galaxies: Young Starbursts at z~2

We present a comprehensive analysis of the rest-frame UV to near-IR spectral energy distributions and rest-frame optical spectra of four of the brightest gravitationally lensed galaxies in the literature: RCSGA 032727-132609 at z=1.70, MS1512-cB58 at z=2.73, SGAS J152745.1+065219 at z=2.76 and SGAS J122651.3+215220 at z=2.92. This includes new Spitzer imaging for RCSGA0327 as well as new spectra, near-IR imaging and Spitzer imaging for SGAS1527 and SGAS1226. Lensing magnifications of 3-4 magnitudes allow a detailed study of the stellar populations and physical conditions. We compare star formation rates as measured from the SED fit, the H-alpha and [OII] emission lines, and the UV+IR bolometric luminosity where 24 micron photometry is available. The SFR estimate from the SED fit is consistently higher than the other indicators, which suggests that the Calzetti dust extinction law used in the SED fitting is too flat for young star-forming galaxies at z~2. Our analysis finds similar stellar population parameters for all four lensed galaxies: stellar masses 3-7*10^9 M_sun, young ages ~ 100 Myr, little dust content E(B-V)=0.10-0.25, and star formation rates around 20-100 M_sun/yr. Compared to typical values for the galaxy population at z~2, this suggests we are looking at newly formed, starbursting systems that have only recently started the build-up of stellar mass. These results constitute the first detailed, uniform analysis of a sample of the growing number of strongly lensed galaxies known at z~2.Comment: 13 pages, 8 figures, Accepted to Ap

A Rigorous Derivation of Electromagnetic Self-force

During the past century, there has been considerable discussion and analysis of the motion of a point charge, taking into account "self-force" effects due to the particle's own electromagnetic field. We analyze the issue of "particle motion" in classical electromagnetism in a rigorous and systematic way by considering a one-parameter family of solutions to the coupled Maxwell and matter equations corresponding to having a body whose charge-current density $J^a(\lambda)$ and stress-energy tensor $T_{ab} (\lambda)$ scale to zero size in an asymptotically self-similar manner about a worldline $\gamma$ as $\lambda \to 0$. In this limit, the charge, $q$, and total mass, $m$, of the body go to zero, and $q/m$ goes to a well defined limit. The Maxwell field $F_{ab}(\lambda)$ is assumed to be the retarded solution associated with $J^a(\lambda)$ plus a homogeneous solution (the "external field") that varies smoothly with $\lambda$. We prove that the worldline $\gamma$ must be a solution to the Lorentz force equations of motion in the external field $F_{ab}(\lambda=0)$. We then obtain self-force, dipole forces, and spin force as first order perturbative corrections to the center of mass motion of the body. We believe that this is the first rigorous derivation of the complete first order correction to Lorentz force motion. We also address the issue of obtaining a self-consistent perturbative equation of motion associated with our perturbative result, and argue that the self-force equations of motion that have previously been written down in conjunction with the "reduction of order" procedure should provide accurate equations of motion for a sufficiently small charged body with negligible dipole moments and spin. There is no corresponding justification for the non-reduced-order equations.Comment: 52 pages, minor correction

Electromagnetic self-forces and generalized Killing fields

Building upon previous results in scalar field theory, a formalism is developed that uses generalized Killing fields to understand the behavior of extended charges interacting with their own electromagnetic fields. New notions of effective linear and angular momenta are identified, and their evolution equations are derived exactly in arbitrary (but fixed) curved spacetimes. A slightly modified form of the Detweiler-Whiting axiom that a charge's motion should only be influenced by the so-called "regular" component of its self-field is shown to follow very easily. It is exact in some interesting cases, and approximate in most others. Explicit equations describing the center-of-mass motion, spin angular momentum, and changes in mass of a small charge are also derived in a particular limit. The chosen approximations -- although standard -- incorporate dipole and spin forces that do not appear in the traditional Abraham-Lorentz-Dirac or Dewitt-Brehme equations. They have, however, been previously identified in the test body limit.Comment: 20 pages, minor typos correcte

Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial

PURPOSE: Subcutaneous APF530 provides controlled sustained release of granisetron to prevent acute (0-24 h) and delayed (24-120 h) chemotherapy-induced nausea and vomiting (CINV). This randomized, double-blind phase 3 trial compared APF530 and palonosetron in preventing acute and delayed CINV after moderately (MEC) or highly emetogenic chemotherapy (HEC). METHODS: Patients receiving single-day MEC or HEC received single-dose APF530 250 or 500 mg subcutaneously (SC) (granisetron 5 or 10 mg) or intravenous palonosetron 0.25 mg. Primary objectives were to establish APF530 noninferiority to palonosetron for preventing acute CINV following MEC or HEC and delayed CINV following MEC and to determine APF530 superiority to palonosetron for preventing delayed CINV following HEC. The primary efficacy end point was complete response (CR [using CI difference for APF530 - palonosetron]). A lower confidence bound greater than -15 % indicated noninferiority. RESULTS: In the modified intent-to-treat population (MEC = 634; HEC = 707), both APF530 doses were noninferior to palonosetron in preventing acute CINV after MEC (CRs 74.8 % [-9.8, 9.3] and 76.9 % [-7.5, 11.4], respectively, vs. 75.0 % palonosetron) and after HEC (CRs 77.7 % [-11.5, 5.5] and 81.3 % [-7.7, 8.7], respectively, vs. 80.7 % palonosetron). APF530 500 mg was noninferior to palonosetron in preventing delayed CINV after MEC (CR 58.5 % [-9.5, 12.1] vs. 57.2 % palonosetron) but not superior in preventing delayed CINV after HEC. Adverse events were generally mild and unrelated to treatment, the most common (excluding injection-site reactions) being constipation. CONCLUSIONS: A single subcutaneous APF530 injection offers a convenient alternative to palonosetron for preventing acute and delayed CINV after MEC or HEC

Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): A feasibility study

Background: Concurrent chemoradiotherapy has improved survival in inoperable stage III non-small cell lung cancer (NSCLC). This phase I trial was performed in order to establish a dose recommendation for oral vinorelbine in combination with cisplatin and simultaneous radiotherapy. Patients and Methods: Previously untreated patients with stage IIIB NSCLC received concurrent chemoradiotherapy with 66 Gy and 2 cycles of cisplatin and oral vinorelbine which was administered at 3 different levels (40, 50 and 60 mg/m(2)). This was to be followed by 2 cycles of cisplatin/vinorelbine oral consolidation chemotherapy. The study goal was to determine the maximal recommended dose of oral vinorelbine during concurrent treatment. Results: 11 stage IIIB patients were entered into the study. The median radiotherapy dose was 66 Gy. Grade 3-4 toxicity included neutropenia, esophagitis, gastritis and febrile neutropenia. The dose-limiting toxicity for concurrent chemoradiotherapy was esophagitis. 9 patients received consolidation chemotherapy, with neutropenia and anemia/thrombocytopenia grade 3 being the only toxicities. The overall response was 73%. Conclusion: Oral vinorelbine 50 mg/m(2) (days 1, 8, 15 over 4 weeks) in combination with cisplatin 20 mg/m2 (days 1-4) is the recommended dose in combination with radiotherapy (66 Gy) and will be used for concurrent chemoradiotherapy in a forthcoming phase III trial testing the efficacy of consolidation chemotherapy in patients not progressing after chemoradiotherapy